Physician profile
Robert J Comer
NPI 1134233158
$2,711.51
in general payments reported to CMS, 2019-2025
31 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $185 · 2021: $162 · 2022: $140 · 2023: $383 · 2024: $486 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $571.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $271.24 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $241.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.52 | 2024-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $161.03 | 2021-2023 | |
| Amgen INC. | $114.88 | 2023-2024 | Repatha, Otezla, Tepezza |
| Janssen Pharmaceuticals, INC | $105.76 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $92.80 | 2023-2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $81.16 | 2019-2020 | |
| Allergan, INC. | $77.98 | 2019-2021 | |
| Coloplast Corp | $73.51 | 2019 | |
| Sumitomo Pharma America, INC. | $70.40 | 2024-2025 | Gemtesa |
| Amarin Pharma, INC. | $69.53 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $60.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $51.61 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.61 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $39.95 | 2024-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $36.87 | 2023-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $35.90 | 2022-2024 | |
| Nalpropion Pharmaceuticals LLC | $35.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2022 | |
| Astellas Pharma US INC | $25.07 | 2024 | Veozah |
| Horizon Therapeutics Plc | $23.99 | 2019 | |
| Aimmune Therapeutics, INC. | $22.53 | 2025 | Zenpep |
| Exact Sciences Corporation | $20.78 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $20.75 | 2023 | Freestyle Libre 2 |
| Antares Pharma, INC. | $16.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.40 | 2024 | Zoryve |
| Eisai INC. | $13.63 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Comer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.